BPC-157 + TB-500 (Synergistic Healing Stack)
The BPC-157 + TB-500 combination is the most extensively studied peptide healing stack, combining two complementary tissue-repair mechanisms: BPC-157's growth factor upregulation and NO-mediated angiogenesis with TB-500's actin-mediated cell migration and vascular remodeling. Together, they address more steps in the healing cascade than either compound alone, earning a combined evidence grade of A- for musculoskeletal injury recovery research.
Why This Stack Works: Complementary Mechanisms
BPC-157 Contributions
GH receptor upregulation in tendon fibroblasts
VEGF expression → angiogenesis
eNOS activation → vasodilation, perfusion
FAK-paxillin pathway → cytoskeletal repair
GI mucosal healing (unique to BPC-157)
Anti-inflammatory: NF-kB suppression
TB-500 Contributions
Actin sequestration → cell migration
MMP upregulation → ECM remodeling
Epicardial progenitor cell activation
Anti-inflammatory: inhibits NFkB
Cardiac tissue repair (unique to TB-500)
Hair follicle stem cell activation
The synergy arises because BPC-157 primarily creates the angiogenic and growth factor environment (vascularization, GH receptor sensitization), while TB-500 provides the cellular motility machinery (actin-mediated migration) to actually populate the wound bed with repair-competent cells. Neither mechanism alone is sufficient for optimal healing — together they recapitulate more of the native healing response.
Combined Protocol A-
Phase 1: Acute / Loading (Weeks 1–6)
BPC-157
500 mcg
Once daily (AM or near injury)
SubQ / IM
TB-500
5 mg
Twice weekly (Mon/Thu)
Phase 2: Maintenance (Weeks 7+)
250–500 mcg
5 days/week
SubQ
2.5 mg
Twice monthly
Injury-Specific Notes
Tendon/Ligament: Inject BPC-157 near (not into) affected tissue; add IM if deep injury
Muscle tear: Standard SubQ abdominal; concurrent physiotherapy recommended
GI injury: Oral BPC-157 (500 mcg/day) + SubQ TB-500
Bone fracture: SubQ both compounds; TB-500 loading for 8 weeks
Reconstitution for Stack
2 mL
2500 mcg/mL
0.2 mL (20 units)
1 mL
5000 mcg/mL
0.5 mL = 2.5 mg
Use the Reconstitution Calculator for customized volumes. BPC-157 and TB-500 can be drawn into the same syringe when dosing coincides (e.g., Mon/Thu).
Side Effects & Safety
Both compounds individually have favorable safety profiles in preclinical research
No documented adverse interactions between BPC-157 and TB-500
Combined injection site reactions are no greater than individual compounds
Pro-angiogenic activity: avoid in active malignancy
No hormonal suppression; no PCT required
Human safety data for the combination is limited to observational reports
Key Research Basis
Comprehensive mechanistic review documenting BPC-157's role in angiogenesis, GH receptor upregulation, and FAK pathway activation — the molecular basis for its healing synergy with TB-500.
Documents TB-500's cell migration (actin sequestration) and MMP upregulation mechanisms that complement BPC-157's angiogenic effects in wound healing.
Systematic review of BPC-157 in tendon, ligament, and muscle models; documents mechanisms complementary to TB-500 for combined stack rationale.
Frequently Asked Questions
Explore More
Full BPC-157 compound guide
Full TB-500 compound guide
Add copper peptide to the stack
Browse all 227 compounds
Build healing protocols
Precision stack dosing
Related Resources